NBIO (Nascent Biotech) Operating Margin %: 0.00% (As of Jun. 2024)


What is Nascent Biotech Operating Margin %?

Nascent Biotech NBIO +66.67% Operating Margin % is 0.00% as of Jun. 2024.

Operating Margin % is calculated as Operating Income divided by its Revenue. Nascent Biotech's Operating Income for the three months ended in Jun. 2024 was $-0.38 Mil. Nascent Biotech's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Nascent Biotech's Operating Margin % for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Nascent Biotech's Operating Margin % or its related term are showing as below:


NBIO's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.83
* Ranked among companies with meaningful Operating Margin % only.

Nascent Biotech's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Nascent Biotech's Operating Income for the three months ended in Jun. 2024 was $-0.38 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2024 was $-2.09 Mil.


Nascent Biotech  (OTCPK:NBIO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Nascent Biotech Operating Margin % Related Terms


Nascent Biotech Operating Margin % Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Operating Margin % Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Operating Margin %
Get a 7-Day Free Trial 0.00 -186.67 -45.70 0.00 0.00

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NBIO vs BTAX, PXMD, XSNX: Operating Margin % Comparison

For the Biotechnology subindustry, Nascent Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Operating Margin % falls into.



Nascent Biotech Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Nascent Biotech's Operating Margin % for the fiscal year that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (A: Mar. 2024 ) / Revenue (A: Mar. 2024 )
=-2.23 / 0
= %

Nascent Biotech's Operating Margin % for the quarter that ended in Jun. 2024 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2024 ) / Revenue (Q: Jun. 2024 )
=-0.376 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Nascent Biotech (NBIO) has a Operating Margin % of 0.00% as of Jun. 2024. Operating margin is the ratio of total operating income to net sales. View historical data on Nascent Biotech and its competitors.
Is Nascent Biotech's Operating Margin % too high?
Nascent Biotech's current Operating Margin % is 0.00%.
How does Nascent Biotech's Operating Margin % compare to BTAX and PXMD?
Nascent Biotech's Operating Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Nascent Biotech and its competitors. Nascent Biotech's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current Operating Margin % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.